Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Clinical hallmarks in whole cancer genomes

Nature Reviews Clinical Oncology volume 14, pages 265–266 (2017)Cite this article

Subjects

Fraser and colleagues describe the whole-genome sequencing (WGS) profiles of over 200 localized intermediate-risk prostate cancers. WGS has been widely used in research but not, thus far, in clinical settings. Herein, we consider the possible use of WGS in the field of precision oncology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Illustration of three complex somatic mutational phenomena frequently seen in the whole genomes of both prostate cancers and those of other tumour types.

References

  1. Retterer, K. et al. Clinical application of whole-exome sequencing across clinical indications. Genet. Med. 18, 696–704 (2015).

    Article  Google Scholar 

  2. Stavropoulos, D. J., Merico, D. & Jobling, R. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPJ Genom. Med. 1, 15012 (2016).

    Article  CAS  Google Scholar 

  3. Alioto, T. S. et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat. Commun. 6, 10001 (2015).

    Article  CAS  Google Scholar 

  4. Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364 (2017).

    Article  CAS  Google Scholar 

  5. Roberts, S. A. & Gordenin, D. A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786–800 (2014).

    Article  CAS  Google Scholar 

  6. Tubbs, A. & Nussenzweig, A. Endogenous DNA damage as a source of genomic instability in cancer. Cell 168, 644–656 (2017).

    Article  CAS  Google Scholar 

  7. Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110–120 (2016).

    Article  CAS  Google Scholar 

  8. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226–1236 (2013).

    Article  CAS  Google Scholar 

  9. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).

    Article  CAS  Google Scholar 

  10. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585–598 (2014).

    Article  CAS  Google Scholar 

  11. Khurana, E. et al. Role of non-coding sequence variants in cancer. Nat. Rev. Genet. 17, 93–108 (2016).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dmitry Gordenin PhD of the National Institute of Environmental Health Sciences for his helpful comments and suggestions.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Marcin Imielinski is at The Englander Institute for Precision Medicine, The Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College–New York Presbyterian Hospital, 413 East 69th Street, 14th floor, New York, New York 10021, USA,

    Marcin Imielinski

  2. at New York Genome Center, 101 Avenue of the Americas, New York, New York, 10013, USA.,

    Marcin Imielinski

  3. Department of Pathology and Laboratory Medicine, Mark A. Rubin is at The Englander Institute for Precision Medicine, The Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College–New York Presbyterian Hospital, 413 East 69th Street, 14th floor, New York, New York 10021, USA.,

    Mark A. Rubin

Authors
  1. Marcin Imielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marcin Imielinski or Mark A. Rubin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Imielinski, M., Rubin, M. Clinical hallmarks in whole cancer genomes. Nat Rev Clin Oncol 14, 265–266 (2017). https://doi.org/10.1038/nrclinonc.2017.45

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.45

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer